Home › Funds › 22NW, LP › LFCR
22NW, LP position in LFCR
LIFECORE BIOMEDICAL INC · Health Care
22NW, LP reported holding 1,254 shares of LFCR (LIFECORE BIOMEDICAL INC) in its Q3 2026 13F filing — a position valued at US$8K, representing 0.01% of its reported portfolio and ranking #15 among its reported holdings. 22NW, LP has disclosed LFCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How 22NW, LP's LFCR position evolved
22NW, LP first disclosed a stake in LFCR in Q3 2023 at 1,755,161 shares (US$13.3M). The position peaked in Q4 2024 at 1,755,161 shares, worth US$31.1M. Across 13 filings, 22NW, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 1,254 shares valued at US$8K. Notable position changes include a 85% trim in Q2 2025 (shares fell 9% over the following quarter), a 100% trim in Q3 2025 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.76M | $13.25M | New |
| Q4 2023 | 1.76M | $10.86M | Hold |
| Q1 2024 | 1.76M | $9.32M | Hold |
| Q2 2024 | 1.76M | $24.00M | Hold |
| Q3 2024 | 1.76M | $23.65M | Hold |
| Q4 2024 | 1.76M | $31.15M | Hold |
| Q1 2025 | 1.76M | $29.82M | Hold |
| Q2 2025 | 264.18K | $22.63M | Reduce |
| Q3 2025 | 1.25K | $20.15M | Reduce |
| Q4 2025 | 1.25K | $23.03M | Hold |
| Q1 2026 | 1.25K | $18.87M | Hold |
| Q2 2026 | 1.25K | $6.22K | Hold |
| Q3 2026 | 1.25K | $8.25K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LFCR and 13F data
LFCR (LIFECORE BIOMEDICAL INC) is a Health Care company. 21 other funds we track also report a position in LFCR — the largest reported positions include WYNNEFIELD CAPITAL INC (US$24.7M), Legion Partners Asset Management, LLC (US$23.4M), Greenhaven Road Investment Management, L.P. (US$18.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LFCR
- WYNNEFIELD CAPITAL INC 4.70M sh · $24.69M · Q2 2026
- Legion Partners Asset Management, LLC 4.46M sh · $23.42M · Q2 2026
- Greenhaven Road Investment Management, L.P. 2.87M sh · $18.88M · Q3 2026
- 325 CAPITAL LLC 2.90M sh · $15.20M · Q2 2026
- DCF Advisers, LLC 376.50K sh · $2.48M · Q3 2026
- WITTENBERG INVESTMENT MANAGEMENT, INC. 314.01K sh · $1.65M · Q2 2026
FAQ
How long has 22NW, LP held LFCR?
22NW, LP has disclosed LFCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is 22NW, LP's current position in LFCR?
As of Q3 2026, 22NW, LP holds 1.25K shares of LFCR (LIFECORE BIOMEDICAL INC), valued at $8.25K, representing 0.01% of its reported portfolio and ranking #15.
Has 22NW, LP been buying or selling LFCR?
In the latest 13F filing (Q3 2026), 22NW, LP held unchanged its position in LFCR. The position peaked in Q4 2024 at 1.76M shares.
Which other funds hold LFCR?
Other major institutional holders of LFCR include WYNNEFIELD CAPITAL INC, Legion Partners Asset Management, LLC, Greenhaven Road Investment Management, L.P., among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.